Senti Biosciences (NasdaqCM:SNTI) 2026 Conference Transcript

Summary of Senti Biosciences Conference Call Company Overview - Company: Senti Biosciences - Focus: Development of logic gating and gene circuits for cell therapy, particularly in oncology [3][4] Core Industry Insights - Oncology Drug Development Challenge: The primary challenge is to kill cancer cells without harming healthy cells. Traditional therapies often struggle to find clean targets that minimize side effects [3][4] - Logic Gates Concept: Senti is innovating by using logic gates to enhance the specificity of cell therapies, allowing for the recognition and killing of cancer cells while protecting healthy cells [4][5] Key Product: SENTI-202 - Target Indication: Acute Myeloid Leukemia (AML) is identified as a significant area of unmet need due to the difficulty in finding clean targets for treatment [8][9] - Mechanism: SENTI-202 utilizes two CAR receptors: an activating CAR for cancer targets (CD33 and FLT3) and an inhibitory CAR to protect healthy hematopoietic stem cells via the VSIG2 target [9][10] - Clinical Data: - Phase 1 study showed a 42% complete response (CR) rate in relapsed refractory AML patients, with 100% of CR patients being minimal residual disease (MRD) negative and a median durability of 7.6 months [24][26] - Safety profile was consistent with NK cell therapies, primarily grade 1 or 2 events [24][34] Competitive Landscape - Unmet Need in AML: The median survival for relapsed refractory AML patients is approximately 5.3 months, with existing therapies showing low CR rates (12-20%) [26][27] - Senti's Differentiation: Senti's approach with validated targets (CD33 and FLT3) and the use of engineered NK cells is positioned as a potential best-in-class solution compared to existing NK therapies that have shown lower response rates [82][83] Regulatory and Development Plans - RMAT Designation: Senti has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, facilitating closer collaboration for clinical development [42] - Next Steps: Plans to initiate pivotal trials later this year, with a focus on expanding indications beyond AML to high-risk myelodysplastic syndromes (MDS) [65][66] Future Directions - Solid Tumor Applications: Senti is exploring the application of its technology in solid tumors and other modalities, indicating a broad potential for its logic gating technology [69][70] - Investigator Interest: There is significant interest from major AML centers to participate in upcoming trials, reflecting the high demand for effective treatments in this space [61][62] Additional Considerations - Patient Population: The trial is designed to include a broad range of patients, with a focus on those who can tolerate low-dose chemotherapy [49][51] - Biomarker Selection: Currently, patients must be CD33 positive to participate, but ongoing analyses will continue to refine this requirement [52][54] This summary encapsulates the key points discussed during the conference call, highlighting Senti Biosciences' innovative approach to addressing significant challenges in oncology, particularly in AML treatment.